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Abstract
This review article analyzes, through a nonsystematic approach, the pathophysiology of acute pancreatitis (AP) with
a focus on the effects of thoracic epidural analgesia (TEA) on the disease. The benefit–risk balance is also discussed.
AP has an overall mortality of 1 %, increasing to 30 % in its severe form. The systemic inflammation induces a
strong activation of the sympathetic system, with a decrease in the blood flow supply to the gastrointestinal
system that can lead to the development of pancreatic necrosis. The current treatment for severe AP is
symptomatic and tries to correct the systemic inflammatory response syndrome or the multiorgan dysfunction.
Besides the removal of gallstones in biliary pancreatitis, no satisfactory causal treatment exists. TEA is widely used,
mainly for its analgesic effect. TEA also induces a targeted sympathectomy in the anesthetized region, which results
in splanchnic vasodilatation and an improvement in local microcirculation. Increasing evidence shows benefits of
TEA in animal AP: improved splanchnic and pancreatic perfusion, improved pancreatic microcirculation, reduced
liver damage, and significantly reduced mortality. Until now, only few clinical studies have been performed on the
use of TEA during AP with few available data regarding the effect of TEA on the splanchnic perfusion. Increasing
evidence suggests that TEA is a safe procedure and could appear as a new treatment approach for human AP,
based on the significant benefits observed in animal studies and safety of use for human. Further clinical studies are
required to confirm the clinical benefits observed in animal studies.
Keywords: Thoracic epidural analgesia/anesthesia, Acute pancreatitis, Mortality, Splanchnic perfusion,
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Background
Acute pancreatitis (AP) is one of the most frequent
gastrointestinal diseases requiring hospital admissions
worldwide. In the USA in 2009, AP was responsible for
275,000 hospital admissions with a cost of over US$2.5
billion [1]. The incidence of AP is also increasing due to
an increase of risk factors such as obesity, contributing
to the formation of gallstones, the main cause for devel-
opment of AP [2]. Other frequent etiologies of pancrea-
titis are increased alcohol consumption and aging. The
proportion of each cause varies among the studies, but
gallstones appear to be the first cause of AP, represent-
ing 40–70 % of overall cases [3].
In 80 % of the cases the disease course is mild, but
20 % of patients will experience moderately-severe to se-
vere disease. Despite an overall mortality of 1 %, the se-
vere form of AP is associated with a mortality reaching
30 % [4]. New guidelines, based on evidence-based lit-
erature, emerge every few years and tend to reach con-
sensus on the best clinical management of AP. Besides
the endoscopic removal of gallstones if present, symp-
tomatic treatment remains the cornerstone of medical
therapy in AP. Symptomatic therapy focuses on aggres-
sive rehydration, early nutrition, acceptable analgesia,
oxygenation, and antibiotic use restricted to confirmed
infections [4]. All of these approaches do not have a dir-
ect action on the pancreas itself but try to attenuate the
process of the multiorgan dysfunction syndrome
(MODS) present in the severe form of pancreatitis. No
causal treatment has yet been developed.
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Recent animal and human studies have analyzed the role
of thoracic epidural analgesia (TEA) during AP. Their
hypothesis is that selective segmental sympathectomy
induced by TEA may improve splanchnic perfusion and
induce changes in microcirculation, leading to a better
perfusion of the pancreas [5].
The effect of TEA on splanchnic blood flow is an ac-
tive domain of interest, with conflicting results. Richards
et al. [6] published in 2013 a systemic review which
could not establish the real impact of TEA on splanch-
nic perfusion. Siniscalchi et al. [7] also stated that studies
focusing on regional macrocirculation could not show
an influence on, or even showed worsening of, regional
perfusion when TEA was used. In contrast, studies fo-
cusing on microcirculation, especially in pathologic flow
conditions such as the state induced by AP, suggested
that TEA could improve microcirculation [7]. There is
growing evidence that microcirculation plays a crucial
role in AP, and no treatment except TEA has proven to
play a role in this aspect.
The goal of this article is to describe the pathophysi-
ology of AP and to explore actual knowledge concerning
the effect of TEA on AP by reviewing available animal
and human studies. Furthermore we aim to evaluate the
benefits and risks of TEA, discuss specific aspects
relevant to its clinical application, and investigate its
possible place in disease management.
Pathophysiology of acute pancreatitis
The underlying mechanism of AP is a dysfunction of the
pancreatic acinar cells, resulting from an inappropriate
activation of trypsinogen, the proenzyme of trypsin, in
its active form trypsin [8]. The presence of active trypsin
in the pancreas activates trypsinogen in the gland, lead-
ing to an accumulation of trypsin in the acinar cells
followed by an inflammatory vicious circle. The high
amount of proteolytic enzymes results in local inflam-
mation of the gland, with ongoing damage to the pan-
creas [9, 10] and release of proinflammatory cytokines
interleukin (IL)-1, IL-6, and IL-8 and systemic mediators
such as tumor necrosis factor alpha (TNF-α) inducing a
systemic inflammatory state. This process is often mild
and self-limiting, but the progression of inflammation
can lead to a severe disease graved by local complica-
tions, systemic inflammatory response syndrome (SIRS),
MODS, and death [11]. In the severe form of AP, the
systemic inflammation induces macrovascular and
microvascular alterations, leading to an increased capil-
lary permeability. This in turn induces an interstitial
fluid accumulation with a decreased circulating volume,
causing functional hypovolemia with renal hypoperfu-
sion and acute kidney injury. Pancreatic microvascular
alterations include shunts, vasoconstriction, increased
permeability, edema, and increased leukocyte adhesion
[12]. Pancreatic tissue has been shown to be very sensi-
tive to hypoxemia and ischemia with rapid progression
to necrosis if local circulation is compromised [13]. Cur-
rently the most effective treatment measure is aggressive
fluid resuscitation in order to restore an adequate circu-
lating volume. However, pancreatic circulation during
AP has been proven to be indirectly correlated to car-
diac output. This indirect correlation is due to the
microvasculatory changes happening during AP [12],
thus explaining why even a sufficient systemic perfusion
is sometimes not sufficient to provide an adequate local
perfusion and prevent necrosis.
Two phases have been described in the development
of complications during severe AP: early phase and late
phase. The early phase takes place during the first
10 days and is characterized by SIRS and/or MODS.
During this initial period, a marked hypovolemia is ob-
served, accentuated by increased capillary permeability,
ascites, and ileus, leading in combination with septic
complications to renal dysfunction. Almost half of the
patients with severe AP develop pulmonary complica-
tions, ranging from mild hypoxemia to acute respiratory
distress syndrome [10].
The late phase has been associated with the develop-
ment of infections [14] such as pneumonia and
bacteremia [3, 15, 16] and is characterized by local com-
plications (i.e., pancreatic and peripancreatic necrosis,
peripancreatic fluid collections, pseudocysts, infection
of necrotic tissue) [3]. Moreover, hypovolemia and
hypoxemia due to MODS diminish the oxygen supply
to the pancreas and promote the development of
necrosis. Pancreatic necrosis is a severe complication
because of its secondary infection risk. Infected necro-
sis by gut-derived bacteria is responsible for up to
80 % of mortality in AP [17]. Sterile pancreatic necro-
sis with bacteremia is associated with a high infection
risk, especially when the gastrointestinal barrier is
compromised [18].
Thoracic epidural analgesia in sepsis
Sympathetic blocks induced by TEA have been shown to
induce peripheral and splanchnic vasodilatation, im-
prove gut mucosal perfusion, delay intestinal acidosis in
hypoxia, and increase intramucosal pH in patients with
peritonitis [6]. However, TEA can also lead to functional
hypovolemia and secondary hypotension, which is
mainly seen in the presence of extensive thoracolumbar
block [19]. In the context of sepsis or SIRS, when car-
diovascular dysfunction leads to a reduced vascular tone,
TEA could be deleterious. Daudel et al., investigating the
role of TEA during an experimental model of endotoxe-
mia, showed that an epidural block of T2–T10 did not
impair cardiopulmonary hemodynamic conditions and
global oxygen transport, beyond the changes induced by
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the endotoxin itself. Two hypotheses were formulated to
explain the absence of hypotension in this localized
block: either the localized vasodilatation was sufficiently
compensated by vasoconstriction in nonblocked regions;
or endotoxemia had already induced a maximal vasodila-
tation response, preventing a further decrease secondary
to sympathetic blockade [19].
The bowel mucosa has a particular vascular architec-
ture and is a very vulnerable tissue to hypoperfusion and
hypoxia, requiring extensive amounts of oxygen to main-
tain functional integrity. In sepsis, microvascular dere-
cruitment of vascular beds occurs, thus compromising
the intestinal mucosal barrier and leading to transloca-
tion of bacteria and toxins with secondary bacteremia.
Daudel et al. [20] also investigated the effects of TEA on
gut mucosal microcirculation in septic rats and showed
that TEA increased the density of capillary networks and
improved the quality of gut mucosal perfusion.
The liver, as a main regulator of homeostasis to injury,
sepsis, and inflammation, also represents a target of
TEA. During AP, the activation of the sympathetic system
leads to an increase of catecholamines, inducing activation
of hepatocytes, Kupffer cells, and neutrophilic granulo-
cytes. The resulting cytokine increase of IL-6, TNF-α, and
Fas ligand (FasL) induces systemic inflammation and dir-
ect effects on the liver, causing local hepatic damages and
hepatocyte apoptosis [21]. These hepatic alterations are
worsened by α-adrenergic and β-adrenergic receptor
stimulation, which can induce intrahepatic inflammation
and liver injury in healthy mice without any additional
stimuli. In severe sepsis, liver failure is associated with
increased mortality and length of hospital stay. Hepatic
sympathetic mechanical denervation has been shown to
reduce liver injury during stressful situations [22]. In 2009,
Freise et al. investigated the role of TEA on liver function
in sepsis in rats. They showed a pathological increase in si-
nusoidal blood flow in the AP group, restored to control
values with TEA. No significant changes were noted in
mean blood pressure, cardiac output, hepatic enzymes,
and TNF-α in animals with TEA [22].
Epidural analgesia in animal acute pancreatitis
Animal studies focusing on the role of TEA in AP are
summarized in Table 1. The main findings include mortal-
ity reduction in rats and pigs, reduced metabolic acidosis,
reduced hepatocyte apoptosis and sinusoid vasoconstric-
tion, and improvement of pancreatic and ileal perfusion.
A specific discussion on these articles follows.
In 2006, Demirag et al. [23] showed for the first time
the benefit of TEA on the severity of AP in rats. The
authors evaluated the impact of TEA during AP by
measuring the pancreatic microcirculatory flow and
arterial blood gases, and completed the experiment with
histological analyses to investigate the development of
pancreatic necrosis. TEA partially restored the severe re-
duction in pancreatic blood flow occurring after AP in-
duction, and reduced the severity of metabolic acidosis.
The histopathology, performed less than 5 hours after AP
induction, showed extensive edema and tissue necrosis in
the AP group with less extensive damage in the TEA
group without reaching statistical significance [23].
To investigate the pulmonary repercussions of TEA
during AP, Lauer et al. [24] developed an in-vivo and in-
vitro model of AP and TEA in rats. They showed many
effects of AP on the hemodynamic conditions and lung
function: pulmonary edema, reduced oxygenation, devel-
opment of metabolic acidosis, increased myeloperoxi-
dase activity (marker of neutrophil infiltration in the
lung tissue), and severe endothelial dysfunction. They
showed a beneficial role of TEA with following results:
the AP + TEA group compared with the AP group had
better PaO2 and higher mean arterial pressure and de-
veloped almost no metabolic acidosis, whereas the AP
group developed lactate acidosis. AP also severely im-
paired lung vasoadaptative mechanisms such as hypoxic
pulmonary vasoconstriction (HPV), an important adap-
tative mechanism depending on the integrity of vascular
smooth muscle cells, redirecting blood flow from hyp-
oxic to normoxic regions, and thus optimizing the venti-
lation/perfusion ratio [24]. One of the hypotheses for
HPV impairment is an increased production of nitric
oxide (NO) in pancreatitis. In the context of endothelial
dysfunction, increased NO production, normally known
to be anti-inflammatory and vasodilatative, is thought to
hinder protective vasoconstriction and alter HPV. The
TEA group showed lower levels of exhaled NO, associ-
ated with a better HPV regulation. In the context of
endothelial dysfunction, improvement of HPV by NO
synthase inhibitors is described in the literature [25].
They also investigated receptor-dependent pulmonary
vasoconstriction and found an increased vasoreactivity
to Angiotensin II and to bradykinin in the TEA group,
showing better receptor-dependent vasoconstriction. It
is noteworthy here to signal that bradykinin normally
only induces vasoconstriction when the endothelium is
deficient. The authors discussed this issue with the hy-
pothesis that TEA might improve receptor function it-
self. All of these findings suggest an improved lung
adaptation mechanism to inflammatory injury by TEA.
Hepatic effects of TEA during AP were investigated in a
study published by Freise et al. [26] where they measured
hepatic perfusion by intravital microscopy and FasL
concentration and performed histopathological analysis.
They showed a reduction in sinusoidal vasoconstriction,
without any influence on loss of sinusoids and sinusoidal
perfusion. TEA reduced overall apoptosis and hepatocyte
apoptosis significantly. No significant changes in FasL ex-
pression were noted. These results suggest that TEA plays
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Table 1 Animal studies focusing on the role of thoracic epidural analgesia in acute pancreatitis
First author
and reference
Year Subjects Number Groups Epidural
analgesia
Main measures Findings Comments
Demirag [23] 2006 Rats 19 Three groups:
1) AP [9]
2) TEA [4]
3) AP + TEA [6]
Catheter positioned









- TEA induced a strong increase in
pancreatic microcirculation compared
with AP group
- TEA reduced the severity of metabolic
acidosis
- Histopathological analysis showed that






Lauer [24] 2007 Rats 21 Three groups:
1) AP [7]
2) AP + TEA [7]
3) Shama + TEA [7]
Catheter insertion in
L3– L4, advanced to
T6. Bupivacaine 0.5 %
15 μl/h








by angiotensin and bradykinin
- AP group had more severe metabolic
and lactate acidosis compared with
rats benefitting from TEA
- TEA induced a better arterial oxygenation
and higher mean arterial pressure
compared with AP
- TEA induced a better hypoxic
vasoconstriction response associated
with a reduction of exhaled nitric oxide,
showing less smooth muscle cell
dysfunction compared with AP
- TEA induced a better receptor sensitivity
to angiotensin II and bradykinin compared
with AP
Three different groups
In-vivo and in-vitro analysis
Reproducibility of the
procedure
Freise [26] 2009 Rats 28 + 22 Four groups:
1) Shama + NaCl [7]
2) Shama + TEA (7 + 8)
3) AP + NaCl (7 + 7)
4) AP + TEA (7 + 7)
Catheter insertion in
L3– L4, advanced to









- TEA reduced overall apoptosis and
hepatocyte apoptosis compared with AP
- TEA prevented sinusoid vasoconstriction,
but did not influence loss of sinusoids
and sinusoidal perfusion compared with AP
- TEA did not induce significant changes
in hemodynamic parameters, FasL




Large sample with 22 rats
added for histopathological
analysis and FasL measures
Reproducibility of the
procedure
Freise [18] 2006 Rats 28 Four groups:
1) Shama + NaCl [7]
2) AP + NaCl [7]
3) AP + TEA [7]
4) AP + TEA 7 hours
after AP induction
Catheter insertion in
L3– L4, advanced to
T6. Bupivacaine 0.5 %
15 μl/h






- TEA increased survival at 7 days from
33 to 73 % compared with AP group
- TEA did not induce more hypotension
compared with AP group
- A reduction of 50 % of the ileal arteriolar
perfusion was observed in the AP group,
restored to normal in the AP + TEA and
in delayed TEA groups
- TEA reduced lactate concentration in the
AP + TEA and delayed TEA group compared
with AP
- TEA reduced histologic injury compared
with AP alone, without reaching
statistical evidence
- TEA induced a diminution of IL-6 plasmatic
concentration compared with AP
7 days of follow-up
Data on mortality
Four different groups, one
with delayed
TEA, closer to clinical
situation












Table 1 Animal studies focusing on the role of thoracic epidural analgesia in acute pancreatitis (Continued)
Bachmann [27] 2013 Pigs 34 Two groups:
1) AP + TEA [13]
2) AP alone [21]
Catheter positioned







Laser Doppler flow measures of
pancreas microcirculation
All of the experiment was
realized in ICU settings with
hemodynamic monitoring
and automated infusion system
- TEA improved overall survival at 7 days,
from 29 % in AP group to 82 % in the
group receiving TEA
- TEA improved microcirculation and tissue
oxygenation of the pancreas
- TEA reduced histopathological pancreatic
lesion compared with AP
7 days of follow-up
Data on mortality
Experiment on big animals,
allowing controlled
hemodynamic conditions
such as in ICU settings





aSham defines a group with no induction of acute pancreatitis










a role in hepatic dysfunction occurring during AP by re-
ducing hepatocyte apoptosis [26].
Freise et al. [18] conducted another study in rats
randomized into four groups (TEA without AP, AP,
AP + TEA, and AP + TEA delayed 7 hours after AP
induction), focusing on survival and pancreatic perfusion.
They showed a decrease of 50 % of the ileal mucosal
arteriolar blood flow after induction of AP, which was
restored to normal in the TEA group and the delayed
TEA group. More impressively, they showed an increased
7-day survival rate of 73 % in the AP + TEA group as
compared with 33 % in the AP group (P < 0.05). They also
measured the plasmatic concentration of IL-6, and
showed a significant reduced serum concentration in the
TEA and the delayed TEA groups compared with AP
[18]. This finding is noteworthy since IL-6 contributes to
the disruption of the gastrointestinal barrier, thus promot-
ing bacterial translocation and endotoxemia, and increas-
ing the risk of pancreatic necrosis infection.
Bachmann et al. [27] reported an experimental study in
pigs where one group of animals underwent AP and TEA,
while control animals underwent AP only. During the first
6 hours, all animals had controlled hemodynamic condi-
tions with fluid administration or catecholamine infusion
if needed. Tissue perfusion and oxygenation was mea-
sured by surgical laparotomy. After AP induction, blood
flow and tissue oxygenation diminished rapidly in both
groups, but animals receiving TEA maintained a signifi-
cantly higher perfusion and tissue oxygenation when com-
pared with the control animals. Histopathological analysis
revealed significantly less severe pancreatic lesions in the
group benefiting from TEA. The main outcome of this
study was the 7-day survival, showing 82 % of animals
alive in the TEA group compared with only 29 % in the
control group (P < 0.05) [27]. A main force of this study is
the use of large animals, which allowed the authors to
monitor animals in conditions similar to the intensive care
setting. These results indicate the crucial role of TEA on
mortality in a large animal model of AP.
We have discussed many positive aspects of local anes-
thetics (LA) administered in an epidural way in animals
experiencing AP. There exists evidence that intravenous
LA play an anti-inflammatory role in the lung, the endo-
thelial cells, and the gastrointestinal tract [28]. This is in-
teresting since a considerable resorption of LA occurs in
the systemic circulation [29]. Cassuto et al. [30] in 2006
reviewed the literature concerning the anti-inflammatory
role of LA. The LA from the amino-amide class, such as
lidocaine and bupivacaine, have a dose-dependent anti-
inflammatory action when injected intravenously. They re-
duce leukocyte adhesion and migration, phagocytosis, and
oxygen free radical production. They also reduce the syn-
thesis of inflammatory mediators by inhibition of various
cell membrane-associated enzymes and inhibit cytokines
release such as IL-1, TNF-α, and IL-8 [30]. LA also pos-
sess a bactericidal action mostly related to their concen-
tration and partly to their structure. Ropivacaine appears
to be an exception, showing less or no anti-inflammatory
and bactericidal activity. These results suggest that TEA
might also have an indirect anti-inflammatory action by
its systemic resorption.
Epidural analgesia in human acute pancreatitis – safety
and efficacy
The impact of TEA on the human physiology has been
studied extensively, but is still not fully understood.
Most of the knowledge we have comes from experimental
studies. Human studies focusing on the role of TEA in AP
are summarized in Table 2. The main findings include the
safety of use in patients presenting severe sepsis and septic
shock and an improvement in pancreatic perfusion. Side-
effects (hypotension, epidural abscess) and the protocol of
epidural analgesia are presented. A specific discussion
concerning these articles follows.
Only a few studies have investigated the role of TEA
in humans with AP, and most of them focused on the
safety of use more than on the changes in prognosis.
Bernhardt et al. [31] analyzed the safety of TEA during
AP in a group of 121 patients. The authors could show
that epidural injection of LA was well tolerated, even in
patients with marginal cardiovascular stability. No neuro-
logical or infectious complications were reported. Excel-
lent analgesia was achieved in 72 % of the observation
days by TEA only, without use of systemic analgesic sub-
stances. Only 8 % of LA injections were associated with
hemodynamic changes requiring use of sympathomimetic
drugs. The conclusion of the study was that TEA is a safe
procedure in patients experiencing AP even in its severe
form, and that cardiovascular instability should not be
considered as a contraindication of TEA. However, septic
shock situations should be approached with caution. This
study did not investigate the prognosis of patients, but
postulated an improvement in early mobilization, with
fewer embolic and respiratory complications [31].
To assess the feasibility, practice, and safety of epidural
analgesia in the ICU, Jabaudon et al. [32] published in
2015 a prospective multicenter observational study.
They included 121 patients, of which 38 (31 %) had AP.
Other main causes of inclusion were major surgery
(42 %) and trauma (14 %). Most of the patients presented
organ failure on admission. Criteria for sepsis, severe
sepsis, and septic shock were present in 60 %, 42 %, and
22 % of the patients respectively. The mean length of stay
of the epidural catheter was 11 days with extreme values
ranging from 3 to 38 days.
The observed adverse effects of TEA were the following:
8 % of the patients presented a catheter placement-related
hypotension which responded adequately to intravenous
Windisch et al. Critical Care  (2016) 20:116 Page 6 of 10
Table 2 Human studies focusing on the role of thoracic epidural analgesia in acute pancreatitis
First author
and reference
Year Number Type of study Epidural analgesia Measures Findings Strength of the study
Bernhardt [31] 2002 121 Prospective
observational
study
Catheters were placed in the
thoracolumbar region, varying
from T8 to L3, most of them
being placed between T10
and L1 70 % were thoracic
blocks and 30 % were lumbar
blocks Epidural analgesia was
managed with boli of 3–5 ml
of bupivacaine 0.25 % every
4–6 hours. No continuous
administration
Safety of procedure
Number of doses given
Mortality
Pain
Number of surgeries needed
Days of artificial ventilation
Biological parameters
- The median epidural block length was 4.2 days
- TEA was well tolerated and considered safe
even in severe patients
- Catheter-associated hypotension occurred in
12 % of the cases, manageable without
complication with fluid replacement and amines
- Excellent analgesia was achieved in 72 % of
observation days without additional drugs
- Normalization of pancreatic enzymes
occurred sooner in patients with early
placement of catheter
-13 % of patients required artificial ventilation
(mean 12 days)
- 24 % of patients had accidental removal of
catheter: 7.4 % had three catheters placed,
3.3 % had four catheters placed, without any
infectious complications
- Average duration of ICU was 12.4 days
Large sample, representative
of general population (mean
53.2 years, extremes 15–87)
Precise follow-up of doses
needed to reach sufficient
analgesia




Catheters were placed in the
thoracolumbar region: 89 %
were thoracic blocks and 11 %
were lumbar blocks Each center
had its own epidural protocol:
26 % used levobupivacaine and
74 % used ropivacaine Local
anesthetics were always
combined with sufentanil
Safety of procedure in
severe patients
Mortality
Reason for initiating TEA
Sepsis status
ICU standard measures
- The mean epidural block length was 11 days
- 38 patients (31 %) had acute pancreatitis
- 8 % of patients presented catheter-associated
hypotension, 2.5 % required punctual
administration of vasopressin during the
catheter placement
- 60 % of patients experienced sepsis, 42 % severe
sepsis, 22 % septic shock and showed good
tolerance to TEA
- 65 % of patients required mechanical ventilation
during the ICU stay
- 17 % had accidental removal of catheter
- one case of epidural abscess




Good tolerance in severe
disease
Sadowski [33] 2015 35 Randomized
control trial




All catheters were placed at the
thoracic level between T6 and
T9, reaching a T4–T12 sensitive
block Epidural analgesia was
managed on a patient-controlled
protocol, with continuous infusion
of bupivacaine 0.1 % + fentanyl
2 μg/ml 6–15 ml/h + boli of
3–5 ml every 30–60 min
Safety of TEA in severe AP
patients
CT perfusion protocol on
admission and 72 h (>20 %
difference considered significant)
Pain measure, length of
hospital stay
Use of antibiotics
Admission to ICU Patient
demographics, comorbidities
and etiology of AP
- The median epidural block length was 5.7 days
- More patients increased their pancreatic perfusion
in the group benefitting from TEA compared with
AP (43 % vs 7 % respectively)
- TEA helped reduce visual analog pain score
compared with AP
- No significant differences were noted in ICU
admission
- Less patients in the TEA group required artificial
ventilation compared with AP, without reaching
statistical evidence (7.7 % vs 27.3 %, P = 0.22)
- No differences were observed in locoregional and
systemic complications
- No length of stay difference
Randomized control trial
Study conducted on patients
experiencing severe disease
Blinded radiologist










fluid administration of 250–500 ml; and 2.5 % required
vasopressor therapy during the catheter placement pro-
cedure in addition to the fluid resuscitation. Furthermore,
one case (0.8 %) of epidural abscess was observed, with an
incidence rate higher than reported previously in
anesthesia and perioperative medicine [5]. The authors
admitted that this abscess could have reasonably been
avoided with a strict protocol for catheter insertion and
management. No spinal or epidural hematomas were re-
ported, despite the accidental removal rate of 17 %. Their
study suggested safety of use of TEA during organ failure,
such as that appearing in AP, with the requirements of a
close follow-up looking carefully for signs of infections
and a timely removal of catheters in patients with sus-
pected or known untreated bacteremia [32].
Another randomized prospective pilot study was con-
ducted by Sadowski et al. [33] on 35 patients with severe
forms of AP. Patients were randomized into two groups,
one receiving TEA and the other systemic analgesia. The
primary outcome was safety of TEA in AP patients. TEA
was placed for a median time of 5.7 days, and no
hemodynamic or infectious complications occurred.
Pancreatic perfusion was evaluated by two injected CT
scans at admission and 72 hours later. A significant vari-
ation of pancreatic perfusion was defined as a difference
of at least 20 % between the two time points. Improved
pancreas perfusion (20 % increase or more) was ob-
served for 43 % patients in the TEA group vs 7 % in the
control group. TEA allowed better pain management,
assessed by a visual analog pain scale every 8 hours.
Hospital length of stay and mortality (0 % in both
groups) were not statistically different. This pilot study
showed that TEA increased arterial pancreas perfusion
and was safe for use in patients with severe AP [33].
All of these recent studies suggest that the use of TEA
during AP is safe, and can possibly induce an improve-
ment in pancreatic perfusion. Hypotension should not be
retained as a contraindication for TEA during AP, since it
is manageable by fluid resuscitation or pharmacological
interventions.
Discussion
We have shown throughout this review the existence of
increasing evidence that TEA plays a regulatory role in
many organ dysfunctions during severe AP, such as that
of the pancreas itself, the gut, the liver, and the lungs.
Indeed, TEA improves intestinal blood flow, pancreatic
microcirculation, and lung and liver function, reduces
the extent of pancreatic necrosis, and helps preserve the
gastrointestinal barrier during AP. All of these factors
are crucial in the development of AP complications.
Animal models also showed an important mortality
reduction in animals receiving TEA [18, 27]. All these
findings suggest that TEA is an efficient approach to
reduce the proinflammatory state and improve the
outcome of the disease.
Many questions remain concerning the clinical appli-
cation of TEA: where and when should the catheter be
placed and how long should it stay in place? What block
extension is required? Should only patients with severe
disease benefit from TEA or is there also a benefit for
milder disease? What type of anesthetics should be used?
During the following discussion, we aim to discuss these
practical aspects one by one.
To begin this discussion, it is important to say that
TEA is already used by many clinicians in the context of
AP, mainly for analgesic purposes when conventional an-
algesic therapy is insufficient. To determine where to
place the block, it is relevant to know that pancreas
sympathetic afferent innervations originate in T6–L2
[34]. Knowing that catecholamine release, one of the
main factors contributing to maintaining blood pressure,
occurs by stimulation of the adrenal medulla innervated
by T5–L1 [35], hypotension is one of the awaited side-
effects from pancreatic regional sympathetic blockade.
In most of the human studies we reviewed, the block
was placed either in a low thoracic position or in an apical
lumbar position (Table 2); and in animal experiments, all
of the catheters were positioned in a low thoracic position
(Table 1), with an incidence of hypotension around 10 %.
We could not find pertinent articles concerning extended
blocks to the cardiac region during AP; however, we con-
sider that extending this block to the cardiopulmonary re-
gion might diminish the cardiac response to hypotension
and increase the frequency and severity of hypotension.
Based on existing experimental studies, a low thoracic
block or apical lumbar block should be used, with a pref-
erence for the low thoracic block to minimize the block
extension with regard to the risk of hypotension.
Combined epidural analgesia (CEA) is another ap-
proach to reduce the doses of LA and improve analgesia.
Jabaudon et al. [32] and Sadowski et al. [33] used sufen-
tanil and fentanyl respectively, whereas Bernhardt et al.
[31] used bupivacaine only, with a satisfactory analgesia
in all studies. In a randomized, double-blind trial focus-
ing on postthoratocomy pain, Grider et al. [36] showed
that a combination of hydromorphone with bupivacaine
vs bupivacaine alone resulted in better analgesia with
smaller doses and a reduced hypotension rate in the
CEA group. Another prospective randomized trial realized
in the same context by Tuncel et al. [37] also showed su-
perior pain relief by a combination of sufentanil with ropi-
vacaine vs ropivacaine alone, without significant difference
in the hypotension rate. CEA should therefore be used to
minimize the risk of hypotension.
When comparing animal models with human AP
pathophysiology, it is important to consider that experi-
mental studies mimic a hyperacute model of AP, with
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TEA effective within minutes or hours following the in-
duction of AP. This situation is not realistic for clinical
practice, when TEA could not be performed earlier than
hours or days after induction. The remaining question is
whether the TEA benefits will continue if initiated
within these delays, and which kind of patients could
benefit from this procedure? Bernhardt et al. [31] ob-
served that the earlier TEA was started in humans, the
faster pancreatic specific enzymes decreased in the
serum of patients. This beneficial effect was still ob-
served after several days, suggesting that TEA maintains
a beneficial role even if not installed immediately [28].
To consider which patients should benefit from TEA, it
is crucial to identify patients at high risk of developing a
severe disease, since the purpose of TEA placement is to
avoid further complications and to minimize already
present complications. In the last revision of the Atlanta
Classification [38], the Marshall score [39] – based on
respiratory, renal, and cardiovascular dysfunction – was
defined as a simple, efficient, and universal score to
identify patients experiencing severe disease [38]. We
propose to use the Marshall score as an aid for physi-
cians to identify rapidly severe cases of AP, which should
then benefit from TEA initiated as early as possible.
Another unresolved issue is the optimal length of
treatment, maximizing potential benefits and minimizing
infectious complications. Bernhardt et al. [31] and
Sadowski et al. [33] observed good clinical tolerance and
no infectious complications with a mean in-place cath-
eter duration of 4.2 days and 5.7 days respectively,
whereas Jabaudon et al. [32] also observed good toler-
ance with a mean duration of 11 days, but with one case
of epidural abscess [32]. TEA management is not clearly
standardized and several protocols exist with regard to
avoiding procedure-related complications. We should
keep in mind that epidural abscess is the most feared
and severe complication of TEA, but is rare with ad-
equate management. For example, known untreated
bacteremia should be a sufficient reason to remove the
catheter. Concerning catheter dislocation that happened
in 24 % and 17 % patients in the studies of Bernhardt et
al. [31] and Jabaudon et al. [32] respectively, the catheter
was safely replaced in patients showing no signs of local
infection. Moreover, Jabaudon et al. showed that 74 % of
the patients required only one catheter placement,
whereas two catheters were placed in 15 %, three cathe-
ters in 10 %, and four catheters in 2 %, with a mean
catheter colonization of 22 %. Some centers propose to
change the catheter every 7–10 days to avoid infection
risks. To maximize the effects of TEA, we propose that
the catheter should stay in place as long as it is required
for pain management, since there exists no simple way
to test directly the induced sympathectomy. Catheter re-
placement should be discussed if catheters stay in place
for a period exceeding 7–10 days or if they are acciden-
tally removed. A close follow-up searching for local and
systemic signs of untreated infection is required, and the
catheter should be removed as soon as serious infectious
risks are detected.
Conclusion
There is a real need for new therapeutic approaches for
the treatment of severe AP, for which the mortality is
still high for severe disease. The growing understanding
of the disease has proven that microcirculation plays a
crucial role in the development of pancreatic necrosis.
TEA appears to be a promising complementary ap-
proach, acting on microcirculation and many organs
dysfunctioning in AP which are not influenced by con-
ventional treatment. TEA appears as a safe and effect-
ive procedure in humans experiencing severe AP,
allowing better analgesia and potential benefits. Close
follow-up of patients benefiting from TEA is required
to manage side-effects such as hypotension and avoid
epidural abscess. Multicenter randomized trials are be-
coming mandatory to investigate the effects of TEA on
morbidity and mortality in humans undergoing a severe
form of AP.
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